Status:
UNKNOWN
Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Conditions:
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Eligibility:
All Genders
18+ years
Brief Summary
The COVID-19 epidemic has now raged for more than a year with more than 100 million identified cases and nearly 2.5 million deaths worldwide. Since November 2020, we have been witnessing the emergence...
Detailed Description
SEVASAR is a paired cohort study with retrospective data collection: * Presentation: patients hospitalized for COVID-19 with SARS-CoV-2 variant 20I / 501Y.V1 * Not exposed: patients hospitalized for ...
Eligibility Criteria
Inclusion
- Adult
- Acute symptomatic PCR + COVID with screening
- Hospitalized for acute COVID between 01/01/2021 (or since the setting up of the screening in the center) and 02/28/2021
Exclusion
- Opposition to participation
- Identification of variants other than 20I / 501Y.V1
- Patients infected with SARS-CoV-2 in a nosocomial context
Key Trial Info
Start Date :
March 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2021
Estimated Enrollment :
2200 Patients enrolled
Trial Details
Trial ID
NCT04863547
Start Date
March 11 2021
End Date
May 31 2021
Last Update
April 28 2021
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens Picardie Site Nord
Amiens, France, 80000
2
CHU Angers
Angers, France
3
Centre hospitalier de Béziers
Béziers, France, 34 500
4
hôpital Avicenne
Bobigny, France, 93000